Organ-on-chips are tiny plastic devices that replicate vital physiological functions of body organs using biocompatible microfluidic chambers that contain a 3D culture of many living human cells. Organ-on-chip facilitates replacing animal models and further reduces the number of animals used in research, therefore resulting in the flourishing growth of the global organ-on-chip market. Additionally, advancements in microfluidic technology coupled with an increasing focus on personalized medicine and precision healthcare are projected to boost the market demand. Also, government funding, support, and initiatives in various regions globally have further led to the exponential growth of the global Organ-on-chip industry.
One of the renowned data analytics, and market research firms, Markntel Advisors, published a recent report description titled “Global Organ-on-Chip Market Research Report: By Model Type (Organ-Based Model, Disease-Based Model), By Material (Polydimethylsiloxane (PDMS), Polymer, Glass), By Solution (Products [Instruments, Consumables & Accessories, Software], Services [Custom Services, Standard Services]), By Organ Type (Liver, Intestine, Kidney, Lung, Heart, Other organs), By Application (Toxicology Research, Drug Discovery, Physiological Model Development, Stem cell Research, Tissue regeneration and regenerative Medicines, Others), By End User (Pharmaceutical and Biotechnology Companies, Cosmetics Industry, Academic and Research Institutes, Others) and Others Forecast (2025-2030)”, according to the report, the Global Organ-on-Chip Market size was valued at around USD 126 million in 2024 and is projected to reach USD 950 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 40% during the forecast period (2025-30).
Unlock the potential of the Global Organ-on-Chip Market with our complimentary market report sample, featuring expert analysis on trends, competition, technology, and regulations. Download now and gain valuable insights to inform your business strategy, drive growth, and stay ahead of the competition - Download Now
Established in 2015, the headquarters is in the United States
Altis Biosystems has developed a patented stem cell platform that recreates the human intestinal epithelium, in a high-throughput format, for compound screening and microbiome research for biopharmaceutical companies. Altis Biosystems offers contract research services to help customers with inflammation, barrier function, toxicology, and drug disposition. The company's goal is to improve non-clinical drug development by reducing the need for animal testing, and the time & cost of drug development.
Established in 2015, the headquarters is in Switzerland
Alveolix AG is a private biotech company that develops in vitro systems to improve preclinical decision-making. Their systems are human-based and recreate the microenvironment of cells in the body. The company’s research areas include: Acute lung injury (ALI), Cell Biology, Epithelial cell, Interstitial lung disease, and Molecular biology. Their goal is to improve drug discovery and reduce the need for animal experiments. The company comprises facilities for organ-on-chip production and R&D. Their R&D department includes a cell culture lab, molecular biology lab, and imaging facilities.
Established in 2014 the headquarters is in New Orleans, LA
AxoSim is advancing nerve-on-a-chip technology to improve drug development. Nerve-on-a-chip technology is a 3D cell-based model that acts and functions like a nerve. The technology was developed in the lab of Dr. Michael J. Moore at Tulane University. AxoSim has received funding from the National Science Foundation’s Innovation Corps program. The company’s areas of expertise include Drug development, Preclinical testing, Neurotoxicity, Neuroefficacy, 3D cell assays, Neurodegenerative disease models, Myelination models, Nerve-on-a-chip, Organ-on-a-chip, and Peripheral neuropathy.
Established in 2014, headquarters in Rennes, France
Cherry Biotech offers a complex range of products and services, including CRO 3D in-vitro services, CubiX micro physiological system, and CherryTemp temperature control systems. These solutions aim to help laboratories and pharma companies accelerate their drug development process with greater accuracy and precision while providing alternatives to animal testing. By leveraging innovative technologies and expertise, we offer our clients a competitive advantage in the field of 3D in-vitro research and drug development.
Established in 2015, the headquarters is in the United States
Hesperos, Inc. accelerates drug discovery through the use of Human-on-a-Chip® to provide safety and efficacy data of novel therapeutics for the pharmaceutical, cosmetic, and food industries. This breakthrough technology brings unprecedented insight into how the human body will respond to new drugs enabling the development of treatments for every disease while eliminating the need for animal testing. These services allow research teams to determine how the human body will respond when new drug compounds are introduced – something that previously required costly animal testing and human trials to determine.
The blog comprises Global market players in the organ-on-chip industry, with market product information. This blog entails details regarding the prominent factors behind the surging demand for futuristic growth and new opportunities that facilitate market development. Market players such as Altis Biosystems, AlveoliX AG, Axosim, Bi/ond Solutions B.V, Cherry Biotech, CN-Bio, Emulate, Inc., Hesperos, Inc., Insphero, MesoBioTech, Mimetas B.V., Nortis Inc., React4Life, TARA Biosystems (Valo Health), TissUse GmbH and Other leading companies, facilitate revolutionizing the global market and promoting a secure future for the organ-on-chip market.